Information sur le laboratoire
Talat Bessissow (M.D./M.Sc.)
ChercheurUnité de recherche clinique
Département de médecine (McGill)
Profil de recherche
Mots-clés
Maladie de Crohn • colite ulcéreuse • cicatrisation des muqueuses • néoplasme • pathogenèseIntérêts de recherche
Ma recherche porte sur le rôle de la cicatrisation des muqueuses dans le traitement de la maladie inflammatoire chronique de l'intestin. Je m'intéresse également à l'identification des facteurs qui prédisent la rechute de la maladie.Membre de l'équipe
| Nom | Poste |
|---|
Dernières publications
- Kritzinger, J., Kotrri, G., Lakatos, P. L., Bessissow, T. & Wild, G. (2025). The Role of Biomarkers in Surveillance of Ulcerative Colitis-Associated Colorectal Cancer: A Scoping Review. Journal of clinical medicine, vol. 14.
- Farkas, B., Resál, T., Lakatos, P. L., Bessissow, T., Limdi, J. K., Armuzzi, A., Bezzio, C., Savarino, E. V., Saibeni, S., Michalopoulos, G., Attauabi, M., Seidelin, J. B., Fousekis, F. S., Katsanos, K., Bacsur, P., Bálint, A., Ivány, E., Szepes, Z., Farkas, K. & Molnár, T. (2025). Upadacitinib is associated with better clinical and biochemical outcomes than tofacitinib in refractory, moderate-to-severe UC. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
- Shehab, M., Hassan, A. & Bessissow, T. (2025). Editorial: The Devil Is in the Detail-Interpreting the Findings of Network Meta-Analyses. Authors' Reply. Alimentary pharmacology & therapeutics.
- Li Fraine, S., Marcus, V., Kron, C. M., Lakatos, P. L., Afif, W., Bitton, A., Wild, G. & Bessissow, T. (2025). Impact of Individual Colonic Segment Histological Activity on Disease Relapse in Patients with Ulcerative Colitis. Journal of clinical medicine, vol. 14.
- Shehab, M., Alrashed, F., Alrashidi, A., Hassan, A., Ma, C., Narula, N., Jairat, V., Regueiro, M. & Bessissow, T. (2025). Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease. Alimentary pharmacology & therapeutics, vol. 62, p. 472-482.
- AlBader, B., Jairath, R., Baitalmal, H. & Bessissow, T. (2025). Upadacitinib for the Treatment of Upper Gastrointestinal Crohn's Disease. ACG case reports journal, vol. 12, p. e01749.
- Al Alawi, S., Bessissow, T., Fallone, C. A., Jacques, J. & Barkun, A. (2025). Hemostatic powder's battle against a spurting bleeding ulcer: can it win?. Endoscopy, vol. 57, p. E676-E677.
- De Marco, D., Heron, V., Bitton, A., Bessissow, T., Lakatos, P., Wild, G. & Afif, W. (2025). Assessing the role of ustekinumab dose escalation in Crohn's disease patients with loss of response: an observational study. Journal of the Canadian Association of Gastroenterology, vol. 8, p. 97-102.
- Solitano, V., Ogunsakin, R. E., Yuan, Y., Bernstein, C. N., Bessissow, T., Bressler, B., Hoentjen, F., van Lierop, L., Leung, Y., MaMD, C., Marshall, J. K., Narula, N., Alahmari, M., Mccurdy, J. D., Murthy, S., Panaccione, R., Rosenfeld, G., Milgrom, R., Silverberg, M. & Jairath, V. (2025). Effectiveness and Safety of Advanced Combination Treatment (ACT) in patients with refractory inflammatory bowel disease or concomitant immune mediated disease or extra-intestinal manifestations: A Multi-Center Canadian Study. The American journal of gastroenterology.
- McCurdy, J. D., Macdonald, B., Rosenfeld, G., Bessissow, T., Jairath, V., Bruining, D. H. & Singh, S. (2025). Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply. Alimentary pharmacology & therapeutics, vol. 61, p. 1959-1960.
Voir aussi
